79% of Crohn’s disease patients in remission after early intervention
Led by researchers from the University of Cambridge, a clinical trial examined the effectiveness of giving the immunotherapy drug infliximab earlier, as soon as possible after diagnosis. They employed what’s called a ‘top-down’ strategy, meaning the drug was given straight after diagnosis regardless of the patient’s symptom severity. They found that this early intervention significantly reduces complications of this often debilitating disease, including the need for surgery by a factor of 10.